Treatment

Alice Mwakini, 52, a breast cancer fighter, has been battling the disease for two years. As she was diagnosed in October 2022, she faced uncertainty about what she should eat during her treatment. Like many patients, she sought advice…

(Reuters) - The US Food and Drug Administration imposed a clinical suspension on the drug Kezar Life Sciences (NASDAQ:)' trial of an experimental drug for lupus, the company said Friday. The FDA's decision comes after the company…

TOKYO and CAMBRIDGE, Mass., July 12, 2024 – (JCN NewsWire) – Eisai Co., Ltd. (OTC:) and Biogen Co., Ltd. (NASDAQ:) today announced the approval of the beta-amyloid (Aβ)-degrading monoclonal antibody “LEQEMBI” (generic name: lecanemab) in…

This section is Partnership Content ProvidedThe content in this section has been provided by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Globe…

Eli Lilly & Co. has won U.S. approval for an Alzheimer's treatment, the second drug to slow the progression of the brain-robbing disease that affects 6 million Americans. It's a huge win for Lilly and its investors, who have been…

The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments to the company, BioLight reports. …

(Reuters) -Vertex Pharmaceuticals will buy Alpine Immune Sciences (NASDAQ:) for about $4.9 billion in cash, gaining access to the biotech firm's treatment for an autoimmune disease of the kidney, the companies said on Wednesday. The deal…

AngioDynamics (NASDAQ:ANGO) has secured a label expansion for its AlphaVac F1885 System from the U.S. Food and Drug Administration (FDA). The expanded FDA indication allows for the utilization of the AlphaVac F1885 System for the treatment…

Israeli urology medical device company Vessi Medical today announced the completion of a $16.5 million Series A financing round for its cryotherapy technology to treat non muscle invasive bladder cancer (NMIBC). The…

© Reuters. SAN JOSE, Calif. – Anixa Biosciences, Inc. (NASDAQ: NASDAQ:), a biotech company specializing in cancer treatment, has started treating the fourth patient in its phase 1 clinical trial for a novel ovarian cancer therapy.…